Week In Review: Otsuka Pays $78 Million For Asian Rights To Ariad
Deals and Financings Otsuka Pharma (OTSKF) of Japan snagged marketing rights to Iclusig®, a leukemia drug developed by Ariad Pharma (NSDQ: ARIA), for Japan, China and eight other Asian countries (see story). Otsuka will pay $77.5 million upfront plus additional regulatory milestones. Ariad will receive a “substantial” share of net product revenues. Iclusig, a tyrosine kinase inhibitor,…